Aromatase inhibitors and bone

Journal of Steroid Biochemistry and Molecular Biology

Volumn 106, Issue 1-5, 2007, Pages 157-161

  Eastell, Richard ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Aromatase inhibitors; Bone

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; DENOSUMAB; ESTROGEN; ETIDRONIC ACID; EXEMESTANE; HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBANDRONIC ACID; LETROZOLE; OSTEOCALCIN; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; TAMOXIFEN; UNINDEXED DRUG; VITAMIN D; ZOLEDRONIC ACID;

ACUTE PHASE RESPONSE; AGING; ANKLE EDEMA; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE REMODELING; BONE TURNOVER; BREAST CANCER; CLINICAL TRIAL; CONSTIPATION; FRACTURE; GASTROINTESTINAL DISEASE; HEART INFARCTION; HOT FLUSH; HUMAN; HYPERCALCEMIA; LEG CRAMP; NAUSEA; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; RHINITIS; SIDE EFFECT; STROKE; VENOUS THROMBOEMBOLISM;

AGED; AROMATASE INHIBITORS; BONE AND BONES; BONE DENSITY; FEMALE; FRACTURES, BONE; HUMANS; MIDDLE AGED; RISK FACTORS;

EID: 34548412170     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2007.05.017     Document Type: Article

References (42)

1. Eastell R. Management of bone health in postmenopausal women. Horm. Res. 64 Suppl. 2 (2005) 76-80
2. Delmas P.D. Treatment of postmenopausal osteoporosis. Lancet 359 (2002) 2018-2026
3. Sambrook P., and Cooper C. Osteoporosis. Lancet 367 (2006) 2010-2008
4. US Preventive Services Task Force. Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann. Intern. Med. 137 526 (2002) (ref. type: abstract)
5. Reginster J.Y., Seeman E., de Vernejoul M.C., Adami S., Compston J., Phenekos C., et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J. Clin. Endocrinol. Metab. 90 (2005) 2816-2822
6. Meunier P.J., Roux C., Seeman E., Ortolani S., Badurski J.E., Spector T.D., et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med. 350 (2004) 459-468
7. Storm T., Thamsborg G., Steiniche T., Genant H.K., and Sorensen O.H. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N. Engl. J. Med. 322 18 (1990) 1265-1271
8. Miller P.D., Watts N.B., Licata A.A., Harris S.T., Genant H.K., Wasnich R.D., et al. Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment. Am. J. Med. 103 (1997) 468-476
9. Howell A., Cuzick J., Baum M., Buzdar A., Dowsett M., Forbes J.F., et al. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
10. Coombes R.C., Hall E., Gibson L.J., Paridaens R., Jassem J., Delozier T., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 350 (2004) 1081-1092
11. Thurlimann B., Keshaviah A., Coates A.S., Mouridsen H., Mauriac L., Forbes J.F., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 353 (2005) 2747-2757
12. Coates A.S., Keshaviah A., Thurlimann B., Mouridsen H., Mauriac L., Forbes J.F., Paridaens R., Castiglione-Gertsch M., Gelber R.D., Colleoni M., Lang I., Del Mastro L., Smith I., Chirgwin J., Nogaret J.M., Pienkowski T., Wardley A., Jakobsen E.H., Price K.N., and Goldhirsch A. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 25 5 (2007) 486-492
13. Delmas P.D., Ensrud K.E., Adachi J.D., Harper K.D., Sarkar S., Gennari C., et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J. Clin. Endocrinol. Metab. 87 (2002) 3609-3617
14. Black D.C., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348 (1996) 1535-1541
15. Buzdar A., Howell A., Cuzick J., Wale C., Distler W., Hoctin-Boes G., et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol. (2006) 633-643
16. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 90 (1998) 1371-1388
17. Cuzick J., Forbes J., Edwards R., Baum M., Cawthorn S., Coates A., et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360 (2002) 817-824
18. Grey A.B., Stapleton J.P., Evans M.C., Tatnell M.A., Ames R.W., and Reid I.R. The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. Am. J. Med. 99 (1995) 636-641
19. Resch A., Biber E., Seifert M., and Resch H. Evidence that tamoxifen preserves bone density in late postmenopausal women with breast cancer. Acta Oncol. 37 (1998) 661-664
20. Marttunen M.B., Hietanen P., Tiitinen A., and Ylikorkala O. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. J. Clin. Endocrinol. Metab. 83 (1998) 1158-1162
21. Kristensen B., Ejlertsen B., Dalgaard P., Larsen L., Holmegaard S.N., Transbol I., et al. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. J. Clin. Oncol. (1994) 992-997
22. Ward R.L., Morgan G., Dalley D., and Kelly P.J. Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women. Bone Miner. 22 (1993) 87-94
23. Love R.R., Mazess R.B., Barden H.S., Epstein S., Newcomb P.A., Jordan V.C., et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N. Engl. J. Med. 326 (1992) 852-856
24. Barni S., Lissoni P., Tancini G., Ardizzoia A., and Cazzaniga M. Effects of one-year adjuvant treatment with tamoxifen on bone mineral density in postmenopausal breast cancer women. Tumori 82 (1996) 65-67
25. Kalef-Ezra J.A., Pavlidis N., Klouvas G., Karantanas A., Hatzikonstantinou I., and Glaros D. Elemental composition of bone minerals in women with breast cancer treated with adjuvant tamoxifen. Breast Cancer Res. Treat. 37 (1996) 161-168
26. Eastell R., Hannon R.A., Cuzick J., Dowsett M., Clack G., Adams J.E., et al. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the anastrozole, tamoxifen, alone or in combination (ATAC) trial (18233230). J. Bone Miner. Res. 21 (2006) 1215-1223 (ref. type: abstract)
27. Bajetta E., Zilembo N., and Bichisao E. Endocrine effects of nonsteroidal aromatase inhibitors and their clinical impact. J. Clin. Oncol. 20 (2002) 3039-3040
28. Harper-Wynne C., Ross G., Sacks N., Salter J., Nasiri N., Iqbal J., et al. Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention. Cancer Epidemiol. Biomarkers Prev. 11 (2002) 614-621
29. Perez E.A., Josse R.G., Pritchard K.I., Ingle J.N., Martino S., Findlay B.P., et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J. Clin. Oncol. 24 (2006) 3629-3635
30. Gonnelli S., Cadirni A., Caffarelli C., Petrioli R., Montagnani A., Franci M.B., et al. Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane. Bone (2006 August 10)
31. Lonning P.E., Geisler J., Krag L.E., Erikstein B., Bremnes Y., Hagen A.I., et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J. Clin. Oncol. 23 (2005) 5126-5137
32. Brufsky A., Harker W.G., Beck J.T., Carroll R., Tan-Chiu E., Seidler C., Hohneker J., Lacerna L., Petrone S., and Perez E.A. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol. 25 7 (2007) 829-836
33. Eastell R. Risk factors for fracture: 5-year results of the 'Arimadex' (anastrozole), tamoxifen, alone or in combination (ATAC). Calcif. Tissue Int. 78 (2006) S27 (ref. type: abstract)
34. Eastell R., Hannon R.A., Cuzick J., Clack G., and Adams J.E. Effect of anastrozole on bone mineral density: 5-year results of the 'Arimadex' (anastrozole), tamoxifen, alone or in combination (ATAC) study. Calcif. Tissue Int. 78 (2006) S25 (ref. type: abstract)
35. Cummings S.R., Black D.M., Thompson D.E., Applegate W.B., Barrett-Connor E., Musliner T.A., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280 (1998) 2077-2082
36. Harris S.T., Watts N.B., Genant H.K., McKeever C.D., Hangartner T., Keller M., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282 (1999) 1344-1352
37. Reginster J., Minne H.W., Sorensen O.H., Hooper M., Roux C., Brandi M.L., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos. Int. 11 (2000) 83-91
38. Miller P.D., McClung M.R., Macovei L., Stakkestad J.A., Luckey M., Bonvoisin B., et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J. Bone Miner. Res. 8 (2005) 1315-1322
39. Chesnut III C.H., Skag A., Christiansen C., Recker R., Stakkestad J.A., Hoiseth A., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J. Bone Miner. Res. 8 (2004) 1241-1249
40. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282 (1999) 637-645
41. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344 (2001) 1434-1441
42. Chesnut III C., Silverman S., Andriano K., Genant H.K., Gimona A., Harris S., et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am. J. Med. 109 (2000) 267-276 (ref. type: journal (full))